Engage with industrial experts and thought leaders:
David Elder
Director of Product Development
GlaxoSmithKline
Marcus Brewster
Senior Research Fellow Head of Dept. Drug Delivery Research
Johnson and Johnson
Professor Jean Michelle Cardot
Head of Department of Biopharmaceutics and Pharmaceutical Technology
Universite d’Auvergne
Brendan Griffin
Lecturer in Pharmaceutics and Course Director
University College Cork
Mandar Shah
Sr Research Fellow, Topical Small Molecule Development
Johnson and Johnson
Rene Holm
Head of Preformulation
Lundbeck
Ian Walker
Head of Product Leadership
Acacia Pharma
Professor M.N.V Ravi Kumar
Professor of Drug Delivery
University of Strathclyde
-
Wim Oostra
Department Head
Merck
-
Dr. Norbert Rasenack
Teamleader Continuous Manufacturing Downstream, Contin.Manuf Unit within Global R&D
Novartis Pharma
-
Michael Ausborn
Global Head of Formulation Research
F. Hoffmann-La Roche Ltd
Dr Mark Egerton
Chief Executive Officer
Quotient Clinical
-
Michele Pallaoro
Head, Vaccines and Diagnostics
Novartis
-
Sverre Arne Sande
Professsor, Department of Pharmacy
University of Oslo
-
Weiguo Dai
Fellow, Drug Product Development
Johnson and Johnson
-
Mahesh Chaubel
Sr Director, Global R&D
Baxter
John Comer
Chief Scientific Officer
Sirius Analytical
-
Dr Robert Harris
Director, Early Development
Molecular Profiles
-
Michiel Van Speybroeck
Director, Research and Development
Formac Pharmaceuticals
Featured speaker content:
- Big Formulation Breakthroughs
David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory Board Member, joins Andrea Charles from Pharma IQ, to discuss the most critical unmet drug delivery need and the benefits of early formulation testing. Elder shares his insights on how he thinks formulation screening and testing will develop in the next five years and what will be the next big thing in the field.
- Formulation Strategy: Five Years From Now Contributor: David Elder
An exclusive report from Dr David Elder, Director, Externalization group (SCINOVO), GlaxoSmithKline on the benefits of employing early formulation testing, how formulation screening and testing will develop in the next 5-years and why Stem Cell Therapies will represent the next big breakthrough...
Dr Robert Harris
Director, Early Development
Molecular Profiles
Rob has over 30 years experience in pharmaceutical development gained with both blue chip and SME organisations. He has managed the development of formulations for over 50 NCE's covering most dosage forms.
Dr Mark Egerton
Chief Executive Officer
Quotient Clinical
Dr Mark Egerton joined Quotient Clinical, then Pharmaceutical Profiles, as Chief Executive Officer in August 2005. Mark has over 20 years experience in the pharmaceutical and biotech industry and has worked in a range of organisations including large multinational pharmaceutical companies through to private venture funded biotechnology companies. Following his PhD (Biochemistry, University of Edinburgh) and post-doctoral research (Biochemistry, Biozentrum, Basel), Mark began his pharmaceutical R&D career at Novartis (then Sandoz) in Switzerland and then AstraZeneca in the UK. During this time he was responsible for Discovery projects across a number of therapeutic areas including Inflammation, Infectious disease and Metabolic disease.
After 10 years in Pharma R&D, Mark to joined Incyte Pharmaceuticals, a Californian biotechnology company, where he was responsible for a business unit focused on the application of genomic technologies to pre-clinical development. He returned to the UK with Incyte Pharmaceuticals to head up European Business Operations, and was responsible for leading that organisation to record levels of performance. Prior to joining Quotient, Mark was the Chief Business Officer at Oxagen, a UK biotech company focused on novel therapeutics for Respiratory diseases, where he played a key role in securing a $60M series B financing round, one of the largest biotech financings ever in Europe.